Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2010-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Cannabis for Medical Purposes

CMA POLICY

The Canadian Medical Association (CMA), has always recognized the serious requirement of biopharmaceutical companies to address the needs of patients with chronic and serious illnesses. The CMA endorses the development of cannabis for medical purposes.

The CMA endorses the development of cannabis for medical purposes.

CMA supports the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis.
2. Ensure that the development of cannabis for medical purposes is based on sound scientific evidence.
3. Ensure that the development of cannabis for medical purposes is based on sound scientific evidence.
4. Ensure that the development of cannabis for medical purposes is based on sound scientific evidence.
5. Ensure that the development of cannabis for medical purposes is based on sound scientific evidence.
6. Ensure that the development of cannabis for medical purposes is based on sound scientific evidence.
7. Ensure that the development of cannabis for medical purposes is based on sound scientific evidence.
8. Ensure that the development of cannabis for medical purposes is based on sound scientific evidence.
9. Ensure that the development of cannabis for medical purposes is based on sound scientific evidence.
10. Ensure that the development of cannabis for medical purposes is based on sound scientific evidence.

The CMA endorses the development of cannabis for medical purposes.
Harms associated with opioids and other psychoactive prescription drugs

https://policybase.cma.ca/link/policy11535

POLICY TYPE  Policy document
DATE  2015-05-30
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Position statement on prescription drug shortages in Canada

https://policybase.cma.ca/link/policy10756

POLICY TYPE  Policy document
LAST REVIEWED  2017-03-04
DATE  2013-05-25
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

CMA POLICY

Position Statement on Prescription Drug Shortages in Canada

The Canadian Medical Association (CMA) has received concern from doctors about the availability of prescription drugs. The CMA recommends that the federal government work with the provinces and territories to ensure that all necessary medications are available.

Background

The Canadian Medical Association (CMA) has received concern from doctors about the availability of prescription drugs. The CMA recommends that the federal government work with the provinces and territories to ensure that all necessary medications are available.

Recommendations

1. The federal government should work with the provinces and territories to ensure that all necessary medications are available.

2. The CMA should continue to monitor the availability of prescription drugs and report any concerns to the federal government.

3. The CMA should work with the Canadian Pharmacists Association to develop guidelines for the management of prescription drug shortages.

4. The CMA should work with the Canadian Health Information Network to develop a national database of prescription drug shortages.

The CMA recommends that the federal government work with the provinces and territories to ensure that all necessary medications are available.
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE
Parliamentary submission

DATE
2020-08-13

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2012-12-08

TOPICS
Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents